| Literature DB >> 28676352 |
Neera Kapoor1, Kenneth Joseph Ciuffreda2.
Abstract
PURPOSE: This pilot study sought to determine the efficacy of using the Developmental Eye Movement (DEM) test in the adult, acquired brain injury (ABI) population to quantify clinically the effects of controlled, laboratory-performed, oculomotor-based vision therapy/vision rehabilitation.Entities:
Keywords: Accidente cerebro-vascular (ACV)/ictus; Cerebral vascular accident (CVA)/stroke; Daño cerebral traumático (DCT); Developmental Eye Movement (DEM) test; Eye movements; Movimientos oculares; Neuro-optometric rehabilitation; Prueba DEM (Developmental Eye Movement); Rehabilitación neuro-optométrica; Traumatic brain injury (TBI)
Mesh:
Year: 2017 PMID: 28676352 PMCID: PMC5904826 DOI: 10.1016/j.optom.2017.01.001
Source DB: PubMed Journal: J Optom ISSN: 1989-1342
Clinical data regarding subjects, nine of whom had TBI and five of whom had CVA.
| Diagnosis (TBI/CVA) and subject number | TBI1 | TBI2 | TBI3 | TBI4 | TBI5 | TBI6 | TBI7 |
|---|---|---|---|---|---|---|---|
| Present age (years) and Gender | 33M | 48F | 40F | 32M | 43M | 53F | 59F |
| Age at time of insult (years) | 31 | 46 | 38 | 28 | 41 | 52 | 58 |
| Main vision symptoms | Difficulty reading, with frequent loss of place | Difficulty reading, slow with frequent loss of place | Difficulty reading, slow, with periodic | Persistent loss of place while reading, eye strain after 20 min of reading | Difficulty reading, more so with small print | Difficulty reading, blurred vision, eye strain after 1–2 min | Difficulty reading, slow with frequent loss of place |
| Relevant medications | Neurontin (Gabapentin) | Neurontin (Gabapentin) | Inderal (Propranolol), Lamictal (Lamotrigine) | None | None | Ativan (Lorazepam) | None |
TBI, traumatic brain injury; CVA, cerebral vascular accident; M, male; F, female.
Figure 1An image of the Developmental Eye Movement (DEM) test.
Figure 2An image of the OBER2 recording system (Permobil/IOTA Eye Trace) with the second author pictured as the subject.
Figure 3Flow chart of the study design protocol illustrating of the cross-over design component.
Oculomotor testing protocol sequence. Reprinted with permission from Table 1 on page 5 of Brain Research Protocols. 2004; Volume 14.
| Stimulus | Test duration (min) |
|---|---|
| 1. Central fixation | 0.5 |
| 2. Horizontal predictable saccades (+/− 10 deg amplitude, 0.33 cycle/s step intervals) | 0.5 |
| 3. Vertical predictable saccades (+/− 10 deg amplitude, 0.33 cycle/s step intervals) | 0.5 |
| 4. Horizontal random saccades (0.5–10 deg amplitudes, 0.3–3.8 s step intervals) | 0.5 |
| 5. Vertical random saccades (0.5–10 deg amplitudes, 0.3–3.8 s step intervals) | 0.5 |
| 6. Horizontal pursuit (+/− 10 deg amplitudes, 4.1 deg/s velocity) | 1.0 |
| 7. Vertical pursuit (+/− 10 deg amplitudes, 5.4 deg/s velocity) | 1.0 |
| 8. Multiple-line simulated reading (full page, 34 deg centered field, 1–3 deg amplitudes, 1.0 cycle/s step intervals) | 2.0 |
| 9. Single-line simulated reading (12 deg centered field, 3 deg step displacements, 0.33 cycle/s step intervals) | 1.0 |
| 10. Multiple-line silent reading (Visagraph, level 3, 2 selections) | Approximately 7.5 |
| 11. Multiple-line silent reading (Visagraph, level 10, 2 selections) | Approximately 7.5 |
| Total testing time | Approximately 22.5 |
Figure 4Simulated reading dynamic arrays: (A) multiple line and (B) single line.
Oculomotor training protocol sequence. Reprinted with permission from Table 2 on page 5 of Brain Research Protocols. 2004; Volume 14.
| Stimulus | Test duration (min) |
|---|---|
| 1. Central fixation (0 deg, midline) | 1.5 |
| 2. Horizontal predictable saccades (+/− 5 deg amplitude, 0.33 cycle/s step intervals) | 2.0 |
| 3. Horizontal pursuit (+/− 10 deg amplitude, 4.1 deg/s velocity) | 1.5 |
| 4. Multiple-line simulated reading (full page, 34 deg centered field) | 2.0 |
| TRAINING TIME SUBTOTAL= 7.0 min | |
| 5. Leftward fixation (10 deg left of midline) | 1.5 |
| 6. Horizontal predictable saccades (+/− 10 deg amplitude, 0.33 cycles/s step intervals) | 2.0 |
| 7. Horizontal pursuit (+/− 10 deg amplitude, 4.1 deg/s velocity) | 1.5 |
| 8. Single-line simulated reading (13 deg centered field) | 1.0 |
| TRAINING TIME SUBTOTAL = 6.0 min | |
| 9. Rightward fixation (10 deg right of midline) | 1.5 |
| 10. Vertical predictable saccades (+/− 5 deg amplitude, 0.33 cycle/s step intervals) | 2.0 |
| 11. Vertical pursuit (+/− 5 deg amplitude, 4.1 deg/s velocity) | 1.5 |
| 12. Multiple-line simulated reading (full page, 34 deg centered field) | 2.0 |
| TRAINING TIME SUBTOTAL = 7.0 min | |
| 13. Upward fixation (10 deg above midline) | 1.5 |
| 14. Vertical predictable saccades (+/− 10 deg amplitude, 0.33 cycles/s step intervals) | 2.0 |
| 15. Vertical pursuit (+/− 10 deg amplitude, 4.1 deg/s velocity) | 1.5 |
| 16. Single-line simulated reading (13 deg centered field) | 1.0 |
| TRAINING TIME SUBTOTAL = 6.0 min | |
| 17. Downward fixation (10 deg below midline) | 1.5 |
| 18. Horizontal non-predictable saccades (0.5–10 deg amplitudes, 0.3–3.8 s step intervals) | 2.0 |
| 19. Multiple-line simulated reading (full page, 34 deg centered field) | 2.0 |
| TRAINING TIME SUBTOTAL =5.5 min | |
| 20. Central fixation (0 deg, midline) | 1.5 |
| 21. Vertical, non-predictable saccades (0.5–10 deg amplitudes, 0.3–3.8 s step intervals) | 2.0 |
| 22. Single-line simulated reading (13 deg field, centered on midline) | 1.0 |
| TRAINING TIME SUBTOTAL = 4.5 min | |
| TOTAL TRAINING TIME=36.0 min | |
DEM ratio results for TBI, CVA and All subjects.
| Subgroup | Pre-training | Mid-training | Post-training | |
|---|---|---|---|---|
| CVA | 1.68 ± 0.29 | 1.38 ± 0.27 | 1.25 ± 0.20 | >0.05 |
| TBI | 1.55 ± 0.17 | 1.24 ± 0.07 | 1.14 ± 0.07 | <0.035 |
| All (CVA + TBI) | 1.60 ± 0.15 | 1.29 ± 0.10 | 1.18 ± 0.08 | <0.006 |
DEM error results for TBI, CVA and All subjects.
| Subgroup | Pre-training | Mid-training | Post-training | |
|---|---|---|---|---|
| CVA | 7.60 ± 3.96 | 2.80 ± 1.96 | 0 | Sample too small |
| TBI | 12.44 ± 8.48 | 3.00 ± 2.19 | 0 | Sample too small |
| All (CVA + TBI) | 10.71 ± 5.53 | 2.93 ± 1.52 | 0 | <0.031 |